Date:8/17/2010

icense approval, while Nuleusin, a treatment for late stage metastatic renal cell carcinoma, is still under review. Events Subsequent to June 30, 2010 Following the completion of construction of the new EPIAO and TPIAO plant in the first quarter, the SFDA granted Good Manufacturing Practice ("GMP") certification in August 2010. GMP certification will support the future growth of EPIAO and TPIAO in China and serve as an important step towards exploring global biosimilar opportunities. -- Dr. Jing Lou, chief executive officer of 3SBio, commented: "Overall, the business is performing as expected with a strong set of results this quarter and first half and we reiterate our full-year revenue guidance of US$56-60 million. EPIAO's market share by value in the first quarter of 2010 reached an all-time high of 43.3% and for the first time, TPIAO sales accounted for more than 30% of net revenues, providing further evidence that we are successfully diversifying our product mix. We are also pleased to announce that our new EPIAO and TPIAO plant was inspected by the SFDA in July and has been formally certified as GMP compliant. This is a significant milestone for us as we focus on growing our business in China while taking important steps towards exploring global biosimilar opportunities. "

Three months ended June 30, 2010 Unaudited Financial Results

Net revenues. Net revenues increased by 29.5% to RMB105.5 million (US$15.6 million) for the second quarter of 2010 from RMB81.5 million (US$11.9 million) for the same period in 2009. This increase was largely due to continued strength from EPIAO and TPIAO products which increased by 22.9% and 44.6%, respectively, over the same period in 2009. TPIAO remained the Company's second largest revenue contributor in the quarter, accounting for 30.5% of total net revenues. Export sales declined by 16.9% to RMB2.9 million (US$0.4 million), and revenues from our IV Iron Sucrose supplement rose 5
'/>"/>

SOURCE 3SBio Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference